Related Experiment Video
Updated: Nov 3, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer
Yohei Saito1, Atsushi Mizokami2, Kouji Izumi2
1School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Science, Kanazawa University, Kanazawa 920-1192, Japan.
Abstract:
α-Trifluoromethyl chalcones were prepared and evaluated for their antiproliferative activities against androgen-independent prostate cancer cell lines as well as five additional types of human tumor cell lines. The most potent chalcone 5 showed superior antitumor activity in vivo with both oral and intraperitoneal administration at 3 mg/kg. Cell-based mechanism of action studies demonstrated that 5 induced cell accumulation at sub-G1 and G2/M phases without interfering with microtubule polymerization. Furthermore, several cancer cell growth-related proteins were identified by using chalcone 5 as a bait for the affinity purification of binding proteins.
Insights
New α-Trifluoromethyl chalcones show potent antiproliferative effects against prostate cancer. Chalcone 5 demonstrated significant in vivo antitumor activity and elucidated its mechanism of action by identifying key binding proteins.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Prostate cancer, particularly androgen-independent forms, remains a significant therapeutic challenge.
- Developing novel small molecules with potent antitumor activity is crucial for effective cancer treatment.
Purpose of the Study:
- To synthesize and evaluate α-trifluoromethyl chalcones for antiproliferative activity against various human cancer cell lines.
- To investigate the in vivo efficacy and mechanism of action of the most potent chalcone derivative.
Main Methods:
- Synthesis of α-trifluoromethyl chalcones.
- In vitro antiproliferative assays against androgen-independent prostate cancer and other tumor cell lines.
- In vivo antitumor activity assessment in relevant models.
- Cell cycle analysis and microtubule polymerization assays.
- Affinity purification and protein identification to elucidate mechanism of action.
Main Results:
- Several α-trifluoromethyl chalcones exhibited significant antiproliferative effects.
- Chalcone 5 displayed superior in vivo antitumor activity via oral and intraperitoneal administration at 3 mg/kg.
- Chalcone 5 induced cell cycle arrest at sub-G1 and G2/M phases without affecting microtubule polymerization.
- Key cancer cell growth-related proteins interacting with chalcone 5 were identified.
Conclusions:
- α-Trifluoromethyl chalcones represent a promising class of compounds for cancer therapy.
- Chalcone 5 is a potent antitumor agent with a specific mechanism of action involving cell cycle regulation.
- Further investigation into chalcone 5 and its identified protein targets may lead to novel therapeutic strategies for cancer.
